Paolo Ciracì, Medical Oncology Resident at the University Hospital of Pisa, shared a post on X:
“Translational analyses of BREAKWATER (1L BRAF V600E mCRC):
- EC/FOLFOX OS benefit was consistent across molecular subgroups.
- Elevated UV response pathway activity improved OS benefit with EC/FOLFOX.
- Distinct resistance profiles at PD (EC vs EC/FOLFOX).”
Other articles featuring Dr. Ciracì on OncoDaily.
